Dorzolamide Hydrochloride

CHEMBL1201162 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

360.9 g/mol

LogP

—

Phase

4

A hydrochloride salt form of dorzolamide used as an eye drop to treat glaucoma and elevated eye pressure. Like the base form, it lowers intraocular pressure by reducing aqueous humor production.

Moleküler Ağırlık

360,9000 g/mol

TPSA

151,00 Å²

Terapötik Alanlar

Glaucoma Age-Related Macular Degeneration Hypertension

Etki Mekanizması

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl

InChI

InChI=1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1

Molecular Formula

C10H17ClN2O4S3

HBD / HBA

3 / 7

Döndürülebilir Bağlar

3

Ağır Atomlar

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A hydrochloride salt form of dorzolamide used as an eye drop to treat glaucoma and elevated eye pressure. Like the base form, it lowers intraocular pressure by reducing aqueous humor production.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Dorzolamide Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201162. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918132. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Dorzolamide Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C10H17ClN2O4S3
Eş Anlamlılar: 9

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Dorzolamide Hydrochloride

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget